Journal of Bone and Mineral Metabolism

, Volume 36, Issue 6, pp 710–715 | Cite as

Investigation of the relation between bone mass density and serum preptin levels in pre- and postmenopausal women

  • Saeed Nazari Soltan Aahmad
  • Sajjad Nourollahi
  • Faranak KazerouniEmail author
  • Nahid Kianmehr
  • Hamed Hajipour
  • Davoud Sanajou
  • Vahid Hosseini
Original Article


Preptin is a peptide hormone co-secreted with insulin and amylin from pancreatic β cells. It has been demonstrated to have osteogenic effects both in vitro and in vivo. In the present study, serum preptin levels were measured in pre- and postmenopausal women with similar body mass indexes (BMIs) to elucidate its link with bone mineral density (BMD). Sixty women (30 premenopausal and 30 postmenopausal) with low bone mineral density were studied. The BMD scores, serum preptin levels and serum estradiol levels were measured. The correlation between serum preptin and estradiol levels with BMD was assessed. Serum preptin and estradiol levels were significantly lower in the postmenopausal women than the premenopausal subjects [2102.27 ± 918.66 vs. 2667.30 ± 940.41 ng/L (P < 0.05) and 39.32 ± 31.74 vs. 99.24 ± 49.24 pg/ml (P < 0.001), respectively]. The serum preptin levels had weak positive (albeit statistically significant) correlations with estradiol (r = 0.271, P = 0.036), femur neck BMD (r = 0.233, P = 0.035) and total hip BMD (r = 0.287, P = 0.031), but no correlation was observed between serum preptin levels and L1–4 lumbar spine BMD (r = 0.136, P = 0.474). The findings of the present study suggest that serum preptin levels in women decrease after menopause and have a positive correlation with estradiol, femoral and total hip BMDs.


Preptin Bone mass density Estradiol 


Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.


  1. 1.
    Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU. Archiv Osteoporos 6:59–155CrossRefGoogle Scholar
  2. 2.
    Lin X, Xiong D, Peng Y-Q, Sheng Z-F, Wu X-Y, Wu X-P, Wu F, Yuan L-Q, Liao E-Y (2015) Epidemiology and management of osteoporosis in the People’s Republic of China: current perspectives. Clin Interv Aging 10:1017PubMedPubMedCentralGoogle Scholar
  3. 3.
    Bliuc D, Nguyen TV, Eisman JA, Center JR (2013) The impact of nonhip nonvertebral fractures in elderly women and men. J Clin Endocrinol Metab 99:415–423CrossRefGoogle Scholar
  4. 4.
    Tanaka Y, Nakayamada S, Okada Y (2005) Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4:325–328CrossRefGoogle Scholar
  5. 5.
    O’Connor KM (2016) Evaluation and treatment of osteoporosis. Med Clin N Am 100:807–826CrossRefGoogle Scholar
  6. 6.
    Langdahl B, Ferrari S, Dempster DW (2016) Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Therap Adv Musculoskelet Dis 8:225–235CrossRefGoogle Scholar
  7. 7.
    Reid IR (2015) Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11:418–428CrossRefGoogle Scholar
  8. 8.
    Buchanan CM, Phillips AR, Cooper GJ (2001) Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet β-cells and enhances insulin secretion. Biochem J 360:431–439CrossRefGoogle Scholar
  9. 9.
    Cornish J, Callon KE, Bava U, Watson M, Xu X, Lin J, Chan VA, Grey AB, Naot D, Buchanan CM (2007) Preptin, another peptide product of the pancreatic β-cell, is osteogenic in vitro and in vivo. Am J Physiol Endocrinol Metab 292:E117–E122CrossRefGoogle Scholar
  10. 10.
    Liu Y-S, Lu Y, Liu W, Xie H, Luo X-H, Wu X-P, Yuan L-Q, Liao E-Y (2010) Connective tissue growth factor is a downstream mediator for preptin-induced proliferation and differentiation in human osteoblasts. Amino Acids 38:763–769CrossRefGoogle Scholar
  11. 11.
    Whyte MP, Teitelbaum SL, Reinus WR (1996) Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 11:554–558CrossRefGoogle Scholar
  12. 12.
    Li N, Zheng Y-B, Han J, Liang W, Wang J-Y, Zhou J-R, Shen Y, Zhang J (2013) Lower circulating preptin levels in male patients with osteoporosis are correlated with bone mineral density and bone formation. BMC Musculoskelet Disord 14:1CrossRefGoogle Scholar
  13. 13.
    Amso Z, Kowalczyk R, Watson M, Park Y-E, Callon KE, Musson DS, Cornish J, Brimble MA (2016) Structure activity relationship study on the peptide hormone preptin, a novel bone-anabolic agent for the treatment of osteoporosis. Org Biomol Chem 14:9225–9238CrossRefGoogle Scholar
  14. 14.
    Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Investig 115:3318–3325CrossRefGoogle Scholar
  15. 15.
    Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J, Deng HW (2008) Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 23:17–29CrossRefGoogle Scholar
  16. 16.
    Fulzele K, Clemens TL (2012) Novel functions for insulin in bone. Bone 50:452–456CrossRefGoogle Scholar
  17. 17.
    Cornish J, Naot D (2002) Amylin and adrenomedullin: novel regulators of bone growth. Curr Pharm Des 8:2009–2021CrossRefGoogle Scholar
  18. 18.
    Bosetti M, Sabbatini M, Nicolì E, Fusaro L, Cannas M (2013) Effects and differentiation activity of IGF-I, IGF-II, insulin and preptin on human primary bone cells. Growth Factors 31:57–65CrossRefGoogle Scholar
  19. 19.
    El-Eshmawy M, Abdel Aal I (2015) Relationships between preptin and osteocalcin in obese, overweight, and normal weight adults. Appl Physiol Nutr Metab 40:218–222CrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan KK 2017

Authors and Affiliations

  • Saeed Nazari Soltan Aahmad
    • 1
  • Sajjad Nourollahi
    • 1
  • Faranak Kazerouni
    • 1
    Email author
  • Nahid Kianmehr
    • 2
  • Hamed Hajipour
    • 3
  • Davoud Sanajou
    • 4
  • Vahid Hosseini
    • 4
  1. 1.Department of Medical Laboratory Sciences, Faculty of Paramedical SciencesShahid Beheshti University of Medical ScienceTehranIran
  2. 2.Department of RheumatologyIran University of Medical SciencesTehranIran
  3. 3.Department of Reproductive Biology, Faculty of Advanced Medical SciencesTabriz University of Medical SciencesTabrizIran
  4. 4.Department of BiochemistryTabriz University of Medical SciencesTabrizIran

Personalised recommendations